(AVBP) Movement as an Input in Quant Signal Sets
This article provides an in-depth quantitative analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), noting a neutral near and mid-term outlook with a potential breakdown, despite a long-term positive bias. It details AI-generated institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report highlights elevated downside risk and encourages readers to access real-time signals for positioning and risk parameters.
Cantor Fitzgerald reiterates Overweight on ArriVent stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on ArriVent BioPharma (NASDAQ:AVBP), noting the stock's significant surge over the past year. The firm's analysis focuses on upcoming data presentation for ARR-217, the company’s CDH17 antibody-drug conjugate, and its potential efficacy and safety profile against competitor benchmarks. Additionally, H.C. Wainwright recently raised its price target for ArriVent to $47, anticipating positive results from the Phase 3 FURVENT trial expected in the second half of 2026.
ArriVent BioPharma (AVBP) Stock Price, News & Analysis
This article provides a comprehensive overview of ArriVent BioPharma (AVBP) stock, including its current price, analyst ratings, financial health, and company news. It highlights the company's focus on developing precision oncology medicines, with furmonertinib as its lead product candidate for EGFR-mutated non-small cell lung cancer. The analysis covers earnings expectations, short interest, ownership details, and recent news headlines related to the company's research and financial performance.
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $40
Citi has reiterated its Buy rating for ArriVent BioPharma (AVBP.US), maintaining a target price of $40. This indicates a continued positive outlook from the financial institution on the biopharmaceutical company's stock.
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating
Truist Financial has initiated coverage on ArriVent BioPharma (AVBP.US) with a "Buy" rating. This indicates a positive outlook from the financial firm regarding the biotechnology company's stock performance.
Understanding the Setup: (AVBP) and Scalable Risk
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) using AI models, identifying weak near-term sentiment but strong long-term potential. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data, highlighting divergent sentiment across different horizons.
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC
ArriVent BioPharma has licensed exclusive Greater China rights for its MUC16/NaPi2b tetravalent antibody-drug conjugate, AST12608/ARR-002, to Shanghai Allist Pharmaceuticals. The deal includes up to $80.6 million in upfront and milestone payments, plus tiered royalties. This transaction marks the second licensing deal between the two companies, with ArriVent now acting as the licensor for this IND-stage asset.
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50
This article provides an overview of recent analyst ratings for ArriVent BioPharma (AVBP.US), indicating a positive sentiment. Analysts have set price targets ranging from $42 to $50 for the stock. This suggests a potential upside for investors based on current market evaluations.
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
ArriVent BioPharma (NASDAQ:AVBP) has a strong cash position that allows it to fund its operations for at least two years without needing additional capital, assuming its current cash burn rate continues. While the company is currently unprofitable, its substantial cash reserves and minimal debt suggest it can comfortably invest in business growth. Investors should monitor its cash burn relative to its growth initiatives to assess long-term sustainability.
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd.
E Fund Management Co. Ltd. recently acquired 109,328 shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) for approximately $3.8 million, representing a 0.23% stake in the company. Several other institutional investors have also adjusted their positions in AVBP, with collective institutional ownership now at 9.48%. Despite the acquisition and generally positive analyst ratings with an average price target of $44.86, ArriVent BioPharma reported a quarterly loss of $1.05 per share, missing consensus estimates, and analysts forecast continued losses for the current fiscal year.
What is HC Wainwright's Estimate for AVBP FY2027 Earnings?
HC Wainwright has issued an estimate for ArriVent BioPharma's (NASDAQ: AVBP) FY2027 earnings per share at ($4.24), maintaining a "Buy" rating and a $47 price target. This target is above the analyst consensus of $44.86. The company recently reported a Q2 EPS of ($1.05), missing the consensus estimate of ($0.99).
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal
ArriVent BioPharma (AVBP) recently granted Shanghai Allist Pharmaceuticals exclusive rights to develop and commercialize its antibody drug conjugate ARR-002 in Greater China. Despite recent share price pullbacks, the stock's long-term momentum remains constructive. While its Price-to-Book ratio suggests it's about right compared to peers, a Discounted Cash Flow model indicates a potential undervaluation of 56%.
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47
H.C. Wainwright has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and increased its price target to $47. This decision reflects the firm's continued confidence in the biopharmaceutical company's prospects.
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00
HC Wainwright has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $47.00 from $44.00, maintaining a "buy" rating and implying a 59% upside. This comes amidst a generally positive analyst sentiment, with eight analysts rating the stock a "Buy," one a "Hold," and one a "Sell," leading to a consensus "Moderate Buy" rating and an average target price of $44.86. ArriVent BioPharma specializes in developing targeted cancer therapies, including furmonertinib for EGFR-mutated non-small cell lung cancer, despite recently reporting a quarterly EPS miss.
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50
This article provides a quick look at today's analyst ratings for ArriVent BioPharma (AVBP.US), indicating a forecast share price between $40 to $50. It suggests readers use this information to inform their investment decisions regarding the company.
Technical Reactions to AVBP Trends in Macro Strategies
This article provides a technical analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP) trends, highlighting neutral near and mid-term readings but a potentially strong long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis points to an exceptional risk-reward setup targeting a 13.4% gain versus 0.3% risk.
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma reported its second-quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects topline data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026, and its cash and investments of $373.1 million are projected to fund operations into 2028. Additionally, ArriVent is progressing its ADC candidates, ARR-217 and ARR-002, with ARR-217 advancing to Phase 1b dose optimization and ARR-002 nearing its first patient dosing.
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings
ArriVent BioPharma (NASDAQ:AVBP) experienced a 4.7% drop in share price after reporting weaker-than-expected quarterly earnings, missing analyst estimates by $0.06 with a $1.05-per-share loss. Despite the share price decline and significantly lower trading volume, analyst sentiment remains largely positive, holding a "Moderate Buy" consensus rating and an average price target of $44.83. Institutional ownership in the company has also increased, with major firms like BlackRock, Vanguard, and State Street boosting their stakes.
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP
Tema ETFs LLC has acquired a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP), purchasing 57,034 shares valued at approximately $1.98 million, representing a 0.12% stake. This investment is part of broader institutional interest, with other major firms also adjusting their holdings in the company. Despite ArriVent BioPharma missing its recent quarterly earnings expectations, analysts maintain a "Moderate Buy" rating with an average price target of $44.83.
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP
Dimensional Fund Advisors LP significantly increased its stake in ArriVent BioPharma, Inc. by 758.2% in the first quarter, now holding 126,525 shares valued at $2.92 million. Institutional investors and hedge funds collectively own 9.48% of AVBP, with analysts maintaining a "Moderate Buy" consensus and an average price target of $44.83, despite the company missing its recent quarterly earnings estimates.
AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026
ArriVent BioPharma (AVBP) is making strong clinical progress with its late-stage oncology pipeline, particularly with firmonertinib for EGFR-mutant NSCLC. The company also has next-generation ADCs targeting GI and solid tumors advancing. Significant clinical and financial milestones are anticipated in the second half of 2026.
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS
ArriVent BioPharma (NASDAQ:AVBP) reported a quarterly loss of $1.05 per share, missing analysts' consensus estimates by $0.07. Despite the earnings miss, the company's shares rose by 0.2% to $31.46, and institutional investors own 9.48% of the stock. Analyst sentiment remains "Moderate Buy" with an average price target of $44.83.
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma announced its Q2 2026 financial results, with $373.1 million in cash and investments expected to fund operations into 2028. The company highlighted progress in its oncology pipeline, including anticipated topline Phase 3 data for firmonertinib in NSCLC in 2H 2026 and advancements in its ADC programs, ARR-217 and ARR-002.
ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026
ArriVent BioPharma (AVBP) reported its Q2 2026 financial results, including $373.1 million in cash and investments, projected to fund operations into 2028. The company anticipates topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026. Additionally, ArriVent is advancing its ADC pipeline with ARR-217 in Phase 1b dose optimization and preparing to dose the first patient for ARR-002 in Q3 2026.
ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday
ArriVent BioPharma (AVBP) is anticipated to release its Q2 2026 earnings before market open on Friday, August 14th. Analysts project a loss of $0.98 per share, following a $0.96 loss in the previous quarter which missed estimates. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $44.83 from Wall Street analysts.
Trading the Move, Not the Narrative: (AVBP) Edition
This article provides an AI-generated analysis for Arrivent Biopharma Inc. (AVBP), highlighting a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It details specific institutional trading strategies (Long, Momentum Breakout, Short) with entry, target, and stop-loss levels, and offers multi-timeframe signal analysis for support and resistance levels. The report emphasizes an exceptional risk-reward short setup.
Vivo Capital LLC Takes $20.44 Million Position in ArriVent BioPharma, Inc. $AVBP
Vivo Capital LLC has acquired a new stake in ArriVent BioPharma (NASDAQ:AVBP) worth approximately $20.44 million, representing 1.9% of the company and making it their 20th largest holding. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with a consensus price target of $44.83, reflecting optimism for ArriVent's pipeline of targeted cancer therapies. Other institutional investors have also adjusted their positions in AVBP, with hedge funds and institutional investors collectively owning 9.48% of the stock.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts
ArriVent BioPharma (NASDAQ:AVBP) has received a "Moderate Buy" consensus from analysts, with an average 12-month price target of $44.83. The company, a clinical-stage biopharmaceutical firm, opened at $29.82 with a market capitalization of approximately $1.39 billion. Despite missing quarterly earnings estimates with a loss of $0.96 per share, analysts anticipate a full-year loss of about $3.90 per share.
AVBP|Arrivent Biopharma Inc|Price:29.764|Chg%:-0.056
This article provides a detailed overview of Arrivent Biopharma Inc (AVBP) stock, highlighting its current trading price, market capitalization, and a general lack of a comprehensive stock score due to insufficient data. It further explains TradingKey's methodology for generating various stock scores, such as financial health, company valuation, earnings forecast, price momentum, institutional confidence, and risk management, which are based on a multitude of indicators and data points. The article outlines what each score represents and the factors considered in its calculation, despite the scores not being available for AVBP at this time.
Arrivent Biopharma Inc (AVBP) Balance Sheet
This article presents the quarterly and annual balance sheets for Arrivent Biopharma Inc (AVBP), detailing its financial health through assets, liabilities, and shareholders' equity. It includes key financial metrics like cash and short-term investments, total assets, current assets, and liabilities, alongside FAQs explaining the importance of these metrics for investors. The data spans from FY2023Q2 to FY2026Q1, allowing for year-over-year analysis.
Arrivent Biopharma Inc (AVBP) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Arrivent Biopharma Inc's (AVBP) dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock data for AVBP, including its market cap and recent price changes.
Arrivent Biopharma Inc (AVBP) Institutional Confidence
This article provides a brief overview of institutional shareholding in Arrivent Biopharma Inc (AVBP). It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. The company's current stock price, market cap, and links to other financial analysis tools are also included.
Arrivent Biopharma Inc (AVBP) Cash Flow
This article provides an in-depth analysis of Arrivent Biopharma Inc's (AVBP) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial data spanning several years, highlighting trends and specific figures for various cash flow components. The document also includes an FAQ section explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow.
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis
This article provides valuation details for Arrivent Biopharma Inc (AVBP), highlighting its current stock price, market capitalization, and a negative P/E TTM. It indicates key financial metrics and navigation points for further analysis of the company on the TradingKey platform.
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arrivent Biopharma Inc (AVBP) stock, detailing various indicators and moving averages. It offers insights into the stock's current technical ratings, which show a neutral signal based on moving averages and other technical indicators. The analysis includes values and directions for indicators like MACD, RSI, KDJ, and ATR, alongside moving average signals for different timeframes.
AVBP|Arrivent Biopharma Inc|Price:31.730|Chg%:+0.190
This article provides a financial overview of Arrivent Biopharma Inc (AVBP), detailing its stock price, market cap, and key financial statements including income, balance sheet, and cash flow. It highlights the company's latest earnings report from May 2026, showing EPS and revenue forecasts, and presents detailed quarterly and annual financial indicators. The report also addresses frequently asked questions regarding the company's assets, liabilities, equity, and profitability metrics.
AVBP|Arrivent Biopharma Inc|Price:31.730|Chg%:+0.190
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients, with its lead candidate firmonertinib targeting EGFR mutations in NSCLC. The company also develops antibody drug conjugates for gastrointestinal cancers and other solid tumors. This article provides company information, executive details, and institutional shareholding data for AVBP.
ArriVent BioPharma, Inc. Revenue Breakdown – NASDAQ:AVBP
This article provides a basic overview of ArriVent BioPharma, Inc. (NASDAQ: AVBP) on TradingView. It indicates that the primary content would typically include financial data, statements, statistics, dividends, earnings, and segment analysis, but these sections are not populated in the provided text. The article is largely composed of navigation links and platform information, with minimal actual company financial data presented.
AVBP|Arrivent Biopharma Inc|Price:32.020|Chg%:+0.480
Arrivent Biopharma Inc (AVBP) closed at $31.750, up 0.67%, with a market capitalization of $1.44 billion. Analysts have a "Buy" rating for AVBP with a target price of $43.917, indicating over 55% upside potential. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for cancer, with firmonertinib as its lead candidate and a pipeline including antibody-drug conjugates.
Arrivent Biopharma Inc (AVBP) Income Statement
This article provides the quarterly and annual income statements for Arrivent Biopharma Inc (AVBP), detailing its financial performance including operating expenses, R&D expenses, operating profit, net non-operating interest income, and net income. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing AVBP stock. The company reported a net income of -43.32M for the latest quarter and -166.31M for fiscal year 2025.
(AVBP) Volatility Zones as Tactical Triggers
This report analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) with a focus on volatility zones as tactical triggers. It identifies weak near and mid-term sentiment but a strong long-term outlook, with support being tested. The analysis provides specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward parameters.
(AVBP) Volatility Zones as Tactical Triggers
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also provides multi-timeframe signal analysis, including support and resistance levels for different holding periods.
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
LifeSci Capital has reiterated its "Buy" rating for ArriVent BioPharma (AVBP.US) and has kept its target price unchanged at $42. This sustained rating and price target suggest continued confidence from the firm in the biopharmaceutical company's prospects.
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
BTIG has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained positive outlook suggests continued confidence in the company's prospects by the investment firm.
(AVBP) Volatility Zones as Tactical Triggers
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) using AI models to provide tactical trading triggers. It identifies weak near-term sentiment but strong mid and long-term outlooks, outlining specific entry, target, and stop-loss zones for position, momentum, and risk-hedging strategies. The analysis highlights an exceptional risk-reward short setup for AVBP.
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
JonesTrading has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its target price at $45. This action signals continued confidence in the company's prospects by the investment firm.
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings
This page provides a comprehensive overview of ArriVent BioPharma, Inc.'s financial disclosures and SEC filings, including annual reports (10-K), quarterly reports (10-Q), and earnings releases (8-K). It details key corporate events, earnings summaries, and pipeline progress from 2023 to 2026, highlighting clinical advancements in NSCLC and the company's financial position.
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP
This article provides financial information for ArriVent BioPharma, Inc. (NASDAQ: AVBP), specifically focusing on the number of shareholders. It indicates that the company's market is closed with no trades and lists various data providers for its financial and reference data. The document itself does not present the specific number of shareholders, but rather acts as a portal for this information.
Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP
This article focuses on the enterprise value to revenue forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It highlights the financial data available on TradingView for this specific pharmaceutical company. The content appears to be a financial data point from a larger platform rather than an in-depth analysis.
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP
The article focuses on the price-to-earnings forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It provides navigation and structural elements typical for a financial data platform, indicating where users can find financials, news, community, and technical analysis for the company. The content itself seems to be a placeholder or a section title for detailed financial data.
